Symbol not found

:MNKKQ  
0.00
0.00 (0.00%)
Products, Regulatory

Mallinckrodt Announces Enrollment of First Patient in Phase 1/2a Clinical Trial of StrataGraft® for Investigating the Treatment of Full-Thickness Burns

Published: 12/16/2021 12:03 GMT
(MNKKQ) - Mallinckrodt Announces Enrollment of First Patient in Phase 1/2a Stratasoma Clinical Trial of Stratagraft® (allogeneic Cultured Keratinocytes and Dermal Fibroblasts in Murine Collagen - Dsat) for Investigating the Treatment of Full-thickness Burns.
Mallinckrodt Plc - Pursuing Additional Indication for FDA-approved Product As Part of Clinical Development Program.